Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (>= 70 years) patients with advanced non-small cell lung cancer (Energy-GFPC 06-2015 study).
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
non–small cell lung cancer,nivolumab,doublet,carboplatin-based,first-line,energy-gfpc
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要